Veradermics Doses First Patient in a First-in-Human Clinical Trial for VDPHL for the Treatment of Pattern Hair Loss (Androgenetic Alopecia)

VDPHL is a once-daily non-hormonal oral therapeutic being developed as a treatment for pattern hair loss NEW HAVEN, Conn., Nov. 7, 2023 /PRNewswire-PRWeb/ -- Veradermics Inc., a clinical-stage medical dermatology company with a pipeline of first-in-class product candidates targeting...
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Tags: TRI Source Type: news